Daiichi Sankyo Buys Out China Shell Company To Breathe New Life Into Ranbaxy
This article was originally published in The Pink Sheet Daily
Executive Summary
While Daiichi Sankyo has relied on Ranbaxy's sales presence in other emerging markets, it has decided to buy a stake in China to give Ranbaxy's portfolio a second chance in the country.
You may also be interested in...
Slow Growth And Tough Market Make China An Intriguing Puzzle For Indian Companies
MUMBAI - For large Indian drug companies, China has been a traditional and, to an extent, a dreaded rival in the business of pharmaceutical raw materials. Gargantuan Chinese factories that cropped up in the eighties almost killed scores of Indian bulk drug manufacturing units as every pricing strategy the Indian outfits could conceive of failed to beat the quotations offered by Chinese manufacturers to global brand name companies
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.